Clinical trials: Becotatug Vedotin
HNPCC
A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma
This study is a randomized, open-label, multi-center phase II trial evaluating the efficacy and safety of the becotatug vedotin in combination with pucotenlimab regimen in patients with advanced head and neck squamous cell…
- Trial name
- NCT07628855
- Testing
- Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
- Volunteers
- 30 people
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Nasopharyngeal Carcinoma
Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
This exploratory clinical study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma to receive two cycles of becotatug vedotin plus a PD-1 monoclonal antibody, followed by sequential radiotherapy and…
- Trial name
- NCT07555860
- Testing
- Becotatug Vedotin, Toripalimab, Camrelizumab
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of single-agent Becotatug Vedotin as adjuvant therapy in patients with…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy
- Trial name
- NCT07303283
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Kai Hu
Oral Squamous Cell Carcinoma, Head and Neck Cancer
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
This is a phase 2, open-label, single-arm clinical trial evaluating neoadjuvant therapy with Becotatug vedotin (MRG003) combined with Pucotenlimab (HX008) in patients with previously untreated, resectable stage III-IVA oral…
- Conditions
- Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy
- Trial name
- NCT07766889
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Penile Cancer
A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer
Penile cancer is a rare malignant tumor of the male genitourinary system, with 95% being squamous cell carcinoma. Due to social factors, delayed diagnosis is common, leading to a high rate of lymph node metastasis (17%-45% at…
- Trial name
- NCT07497919
- Testing
- Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This randomized controlled trial aims to evaluate the efficacy and safety of Becotatug Vedotin (MRG003), an antibody-drug conjugate (ADC), combined with the PD-1 inhibitor Pucotenlimab as induction therapy for high-risk…
- Trial name
- NCT07524413
- Testing
- Becotatug Vedotin, Pucotenlimab, Gemcitabine + cisplatin (GP)
- Volunteers
- 514 people
- Sponsor
- Sun Yat-sen University
NSCLC (Advanced Non-small Cell Lung Cancer)
Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
This prospective, single-arm, exploratory multicenter clinical study aims to investigate the safety and efficacy of Becotatug vedotin combined with Pucotenlimab (with or without radiotherapy), followed by Pucotenlimab maintenance…
- Trial name
- PRAD2 (NCT07627321)
- Testing
- Pucotenlimab, Becotatug vedotin, Radiotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Anhui Provincial Cancer Hospital
Head and Neck Squamous Cell Carcinoma
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
A multicenter, randomized, double-blind, phase II clinical study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of Becotatug Vedotin for Injection in combination with PD-1 in patients with locally…
- Trial name
- NCT07586124
- Testing
- Becotatug Vedotin for Injection, Pucotenlimab Injection
- Where
- 15 sites in China
- Volunteers
- 80 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma
This is a prospective, open-label, non-randomized, two-cohort, single-arm Phase 2 study in adults with unresectable or recurrent/metastatic head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma.
- Trial name
- NCT07683507
- Testing
- Becotatug Vedotin Combined with PD-1 Inhibitor
- Volunteers
- 60 people
- Sponsor
- Feng Liu
Advanced Refractory Solid Tumors, EGFR Gene Overexpression
Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
This phase II trial evaluates the combination of Becotatug Vedotin (MRG003), an EGFR-targeting ADC, and Pucotenlimab (HX008), a PD-1 inhibitor, in patients with high EGFR expressing advanced refractory solid tumors.
- Trial name
- NCT07712029
- Testing
- Becotatug Vedotin, Pucotenlimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Tianjin Medical University Second Hospital
Oligo-metastatic Cancer
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
The combination of local consolidative therapy for oligometastases with systemic therapy offers the potential for clinical cure and significantly prolongs survival in a subset of patients with advanced metastatic disease.
- Trial name
- NCT07481799
- Testing
- Becotatug Vedotin, SBRT, Systemic Therapy/Standard of Care
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Ming-Yuan Chen
Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of Becotatug Vedotin with Pucotenlimab as a possible neoadjuvant therapyand for locally advanced oral/pharyngeal squamous cell…
- Trial name
- NCT07545083
- Testing
- MRG003+Pucotenlimab
- Volunteers
- 26 people
- Sponsor
- Shanghai Zhongshan Hospital
Cholangiocarcinoma
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
This study tests whether adding becotatug vedotin (EGFR-ADC) to standard chemotherapy plus immunotherapy improves outcomes compared to chemotherapy plus immunotherapy alone as first-line treatment for patients with advanced or…
- Trial name
- NCT07598318
- Testing
- Becotatug Vedotin, Pucotenlimab, Gemcitabine
- Volunteers
- 164 people
- Sponsor
- Sir Run Run Shaw Hospital
Penile Cancer, Penile Squamous Cell Carcinoma (PSCC)
Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile Cancer
This is an open-label, multicenter, single-arm Phase 2 clinical trial evaluating neoadjuvant pucotenlimab (anti-PD-1 immunotherapy) combined with becotatug vedotin (EGFR-targeted antibody-drug conjugate, ADC) for adults with…
- Trial name
- NCT07767266
- Testing
- Pucotenlimab plus Becotatug Vedotin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University
Thyroid Cancer, Tumor
MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer
This study will evaluate whether adding MRG003 to an ongoing treatment regimen can produce confirmed tumor shrinkage in patients with EGFR-positive advanced thyroid cancer whose cancer initially benefited from that regimen and…
- Conditions
- Thyroid Cancer, Tumor, Advanced Thyroid Carcinoma
- Trial name
- NCT07874321
- Testing
- Becotatug Vedotin (MRG003), Lenvatinib, Anti-PD-1 Inhibitor (Continuation of Prior Treatment)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hypopharyngeal Squamous Cell Carcinoma
Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced…
- Trial name
- RESERVE-HC (NCT07665190)
- Testing
- Becotatug Vedotin and Pucotenlimab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
This is a prospective, multicenter, single-arm clinical trial investigating Becotatug Vedotin in combination with Zimberelimab for the treatment of patients with recurrent and metastatic cervical cancer, vulvar cancer, and…
- Trial name
- NCT07424664
- Testing
- Becotatug Vedotin in combination with Zimberelimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locally Advanced Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
This study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1…
- Trial name
- NCT07524452
- Testing
- Neoadjuvant and Adjuvant Becotatug Vedotin, Neoadjuvant and Adjuvant Immunotherapy, Surgery
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Ming-Yuan Chen
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
This study is a prospective, single-arm, single-center Phase Ib clinical trial of Becotatug Vedotin in combination with cisplatin and concurrent radiotherapy for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07697040
- Testing
- Becotatug Vedotin Combined with Cisplatin and Concurrent Radiotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Hebei Medical University Fourth Hospital
Nasopharyngeal Cancinoma (NPC)
MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial
This study was designed to compare the efficacy and safety of Becotatug Vedotin (MRG003) combined with Pucotenlimab as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT07381699
- Testing
- Becotatug Vedotin and Pucotenlimab
- Volunteers
- 30 people
- Sponsor
- West China Hospital